After a fruitless search for patients with a specific type of prostate cancer, Janssen is suspending a phase 1 clinical trial that was being conducted with ESSA Pharma’s experimental small-molecule inhibitor.

Selective serotonin reuptake inhibitors, or SSRIs, can take weeks or even longer to show efficacy in depressed patients. They also come with a list of potential side effects and, in many patients, fail to work at all. Now, scientists have developed a compound that they believe could circumvent these issues—with promising initial results in mice.

On the backs of a waning COVID-19 pandemic and global supply chain disruptions, the FDA expects that a broader slowdown in the pace of medtech innovation will result in a dip in the number of new devices approved by the agency this year.

An increasingly bitter conflict between biotech and investor has come to a close, with U.K.-based Mereo BioPharma losing out to Rubric Capital Management and handing the activist investor four spots on its board.

A month after Eisai reported positive, topline phase 3 data of its Alzheimer’s treatment lecanemab, STAT News is out with a new bombshell report that gut-checks the drug’s hype.

Evidence is growing that insulin resistance drives Alzheimer’s disease development, and several medications used to treat diabetes are in clinical trials to see whether they can combat the condition. Now, new findings about the way insulin is delivered to the brain suggest it’s worth looking into a broader range of diabetes drugs than previously thought.

In recent years, 23andMe has repositioned itself as a genetic testing company that does more than help users fill out their family trees, but also answer crucial questions about their predispositions for potential conditions.

DiaMedica Therapeutics’ ReMEDy2 trial remains on clinical hold, with the FDA requesting more data to allay its concerns about how the potential stroke drug is administered intravenously.

There’s no shortage of recent studies showing that women are significantly less likely than men to receive the healthcare they need—due in large part to a lack of research and education around sex-based differences in therapies from both the pharma and medtech industries.

GSK has dumped one of its top pipeline prospects. While two of the three phase 3 trials of otilimab hit their primary endpoints, the Big Pharma concluded the efficacy fell short of the level needed to take the anti-GM-CSF antibody forward in rheumatoid arthritis (RA).